A randomized controlled trial (clinicaltrials.gov: NCT0043868) showed that nasal insulin (20–40 UI for 4 months) preserved cognitive measures (ADAS-Cog) and cerebral glucose metabolism (PET imaging) in subjects with MCI or mild-to-moderate AD [43]. The gene discussed is INS; the disease is Alzheimer disease.